MODULATION OF THE TGF-β SIGNALING PATHWAY IN THE TREATMENT OF ENDOMETRIAL HYPERPLASIA WITH GESTAGENS

Details: Created: 15 September 2025; Hits: 333

Autors:

Sarkisyan R. M.

- VOL 5, No. 3 (2025)
DOI: 10.14489/lcmp.2025.03.pp.023-033
Article type: Research Article

Continuous numbering: 17
Pages: 23-33
Share:

Heading: Original Articles

Objective. This study aimed to investigate the effect of progestogens on key components of the transforming growth factor beta (TGF-β) signaling pathway in the endometrial mucosa in cases of non-atypical endometrial hyperplasia, in order to determine the pathogenetic role of this pathway and to predict treatment outcomes. Materials and Methods. A comprehensive examination was conducted on 19 patients with non-atypical endometrial hyperplasia before and after 3 months of conservative treatment with progestogens. Endometrial samples were obtained by dilatation and curettage or Pipelle biopsy. Results. The study revealed that progestogens suppress the upregulated expression of TGF-β observed in endometrial hyperplasia and modulate the altered expression of other components of the TGF-β-dependent signaling pathway, particularly SMAD proteins ( From the name of the Drosophila MAD gene (mothers against decapentaplegic) and the Caenorhabditis elegans SMA gene (small worm phenotype), restoring them to levels typical of normal endometrium. Conclusion. These findings confirm that components of the TGF-β signaling pathway are altered in endometrial hyperplasia and are sensitive to modulation by progestogen therapy. This opens new perspectives for the treatment of this condition and for the prevention of malignant transformation of the endometrial lining leading to endometrial carcinoma.

Rita M. Sarkisyan – postgraduate student, National Medical Research Center of Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov of the Ministry of Health of the Russian Federation, Moscow, Russia.

1. Dumanovskaya MR, Chernukha GE, Tabeeva GI, et al. Endometrial hyperplasia: search for optimal solutions and strategies. Akusherstvo i Ginekologiia. 2021;4:23-31. DOI: 10.18565/aig.2021.4.23-31
2. Zakrzewski PK. Canonical TGFβ signaling and its contribution to endometrial cancer development and progression – underestimated target of anticancer strategies. J Clin Med. 2021;10(17):3900. DOI: 10.3390/jcm10173900
3. Ruiz-Mitjana A, Navaridas R, Vidal-Sabanes M, et al. Lack of extracellular matrix switches TGF-β induced apoptosis of endometrial cells to epithelial to mesenchymal transition. Sci Rep. 2022;12(1):14821. DOI: 10.1038/s41598-022-18976-1
4. Chen PY, Qin L, Simons M. TGFβ signaling pathways in human health and disease. Front Mol Biosci. 2023;10:1113061. DOI: 10.3389/fmolb.2023.1113061
5. Zhao H, Wei J, Sun J. Roles of TGF-β signaling pathway in tumor microenvironment and cancer therapy. Int Immunopharmacol. 2020;89:107101. DOI: 10.1016/j.intimp.2020.107101
6. Kriseman M, Monsivais D, Agno J, et al. Uterine double-conditional inactivation of Smad2 and Smad3 in mice causes endometrial dysregulation, infertility, and uterine cancer. Proc Natl Acad Sci U S A. 2019;116(9):3873-82. DOI: 10.1073/pnas.1806862116
7. Lv M, Chen P, Bai M, et al. Progestin resistance and corresponding management of abnormal endometrial hyperplasia and endometrial carcinoma. Cancers (Basel). 2022;14(24):6210. DOI: 10.3390/cancers14246210
8. Fedotcheva TA. Clinical use of progestins and their mechanisms of action: present and future (review). Sovremennye Tekhnologii v Meditsine. 2021;13(1):93-108. DOI: 10.17691/stm2021.13.1.11
9. Badlaeva AS, Vardanyan MA, Chekeneva NA, et al. Immunohistochemical evaluation of epithelial-mesenchymal transition markers in various forms of endometriosis. Sovremennye Problemy Nauki i Obrazovaniya. 2025;1. DOI: 10.17513/spno.33810
10. Cizkova K, Foltynkova T, Gachechiladze M, et al. Comparative analysis of immunohistochemical staining intensity determined by light microscopy, ImageJ and QuPath in placental Hofbauer cells. Acta Histochem Cytochem. 2021;54(1):21-9. DOI: 10.1267/ahc.20-00032
11. Omelchenko VP, Demidova AA. Informatics, medical informatics, statistics. Moscow: GEOTAR-Media; 2021. 608 p. DOI: 10.33029/9704-5921-8-MIS-2021-1-608
12. Rodriguez GC, Rimel BJ, Watkin W, et al. Progestin treatment induces apoptosis and modulates transforming growth factor-? in the uterine endometrium. Cancer Epidemiol Biomarkers Prev. 2008;17(3):578-84. DOI: 10.1158/1055-9965
13.Delbandi AA, Mahmoudi M, Shervin A, et al. Evaluation of apoptosis and angiogenesis in ectopic and eutopic stromal cells of patients with endometriosis compared to non-endometriotic controls. BMC Womens Health. 2020;20(1):3. DOI: 10.1186/s12905-019-0865-4
14. Wang F, Qualls AE, Marques-Fernandez L, et al. Biology and pathology of the uterine microenvironment and its natural killer cells. Cell Mol Immunol. 2021;18:2101-13. DOI: 10.1038/s41423-021-00739-z
15. Chemerinski A, Garcia de Paredes J, Blackledge K, et al. Mechanisms of endometrial aging: lessons from natural conceptions and assisted reproductive technology cycles. Front Physiol. 2024;28(15):1332946. DOI: 10.3389/fphys.2024.1332946
16. Mandelbaum RS, Ciccone MA, Nusbaum DJ, et al. Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy. Am J Obstet Gynecol. 2020;223(1):103. DOI: 10.1016/j.ajog.2019.12.273
17. Yu HF, Yang ZQ, Xu MY, et al. Yap is essential for uterine decidualization through Rrm2/GSH/ROS pathway in response to Bmp2. Int J Biol Sci. 2022;18(6):2261-76. DOI: 10.7150/ijbs.67756
18. Yang B, Hu M, Fu Y, et al. LASS2 mediates Nrf2-driven progestin resistance in endometrial cancer. Am J Transl Res. 2021;15(13):1280-9.
19. Reis FM, Ribeiro MF, Maia AL, et al. Regulation of human endometrial transforming growth factor ?1 and ?3 isoforms through menstrual cycle and medroxyprogesterone acetate treatment. Histol Histopathol. 2002;17:739-45. DOI: 10.14670/HH-17.739
20. Kumari A, Shonibare Z, Monavarian M, et al. TGF? signaling networks in ovarian cancer progression and plasticity. Clin Exp Metastasis. 2021;38(2):139-61. DOI: 10.1007/s10585-021-10077-z
21. Zubrzycka A, Migdalska-Sek M, Jedrzejczyk S, et al. The expression of TGF-?1, SMAD3, ILK and miRNA-21 in the ectopic and eutopic endometrium of women with endometriosis. Int J Mol Sci. 2023;24(3):2453. DOI: 10.3390/ijms24032453
22. Kriseman ML, Tang S, Liao Z, et al. SMAD2/3 signaling in the uterine epithelium controls endometrial cell homeostasis and regeneration. Commun Biol. 2023;6(1):261. DOI: 10.1038/s42003-023-04619-2
23. Kriseman M, Monsivais D, Agno J, et al. Uterine double-conditional inactivation of Smad2 and Smad3 in mice causes endometrial dysregulation, infertility, and uterine cancer. Proc Natl Acad Sci U S A. 2019;116(9):3873-82. DOI: 10.1073/pnas.1806862116
24. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43-6. PMID: 2081237.
25. Clinical guidelines. Endometrial hyperplasia. Moscow: Ministry of Health of the Russian Federation; 2023. 56 p. (In Russ).

The article can be purchased
electronic!

PDF format

700 руб

DOI: 10.14489/lcmp.2025.03.pp.023-033
Article type: Research Article
Make a request

Keywords

Keywords: endometrial hyperplasia, progestagens, transforming growth factor beta, expression, treatment, prevention.

Use the reference below to cite the publication

Sarkisyan RM. Modulation of the TGF-β signaling pathway in the treatment of endometrial hyperplasia with gestagens. Laboratory and Clinical Medicine. Pharmacy. 2025;5(3):23-33. (In Russ). DOI: 10.14489/lcmp. 2025.03.pp.023-033